Medicus Pharma (MDCX) director awarded 25,000-share stock option grant

Rhea-AI Filing Summary

Medicus Pharma Ltd. reported a new stock option grant to a director. On December 16, 2025, the director received a stock option to buy 25,000 common shares of Medicus Pharma at an exercise price of $1.8 per share, expiring on December 16, 2030.

The option is scheduled to vest quarterly in four equal installments over one year, aligning the director’s potential equity ownership with short-term company performance. Following this grant, the director beneficially owns 25,000 derivative securities, held as a direct ownership position.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ashton William

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PA 19428

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.8	12/16/2025		A		25,000		(1)	12/16/2030	Common Shares	25,000	$0	25,000	D

Explanation of Responses:

1. The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year.

	/s/ Raza Bokhari, as Attorney-in-Fact, for William L. Ashton	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Medicus Pharma (MDCX) report in this Form 4?

The filing reports that a director of Medicus Pharma Ltd. received a stock option on December 16, 2025 to purchase 25,000 common shares at an exercise price of $1.8 per share, expiring on December 16, 2030.

What are the key terms of the new Medicus Pharma (MDCX) stock option grant?

The director was granted a stock option (right to buy) covering 25,000 common shares at an exercise price of $1.8, with an expiration date of December 16, 2030. The option price of the derivative security itself is listed as $0.

How does the Medicus Pharma (MDCX) director’s option vest?

According to the explanation, the option granted on December 16, 2025 is scheduled to vest quarterly in four equal installments over one year, meaning the 25,000 options vest in four equal tranches across that year.

How many derivative securities does the Medicus Pharma director own after this transaction?

After the reported transaction, the director beneficially owns 25,000 derivative securities, corresponding to the 25,000 stock options reported, and this ownership is shown as Direct (D).

Who signed the Medicus Pharma (MDCX) Form 4 and in what capacity?

The Form 4 is signed as /s/ Raza Bokhari, as Attorney-in-Fact, for William L. Ashton, indicating that Raza Bokhari signed on behalf of William L. Ashton under a power of attorney.

What is the relationship of the reporting person to Medicus Pharma (MDCX)?

The filing indicates that the reporting person is a Director of Medicus Pharma Ltd., as shown by the checked box next to the Director relationship.